Evgen Pharma (EVG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.80p
   
  • Change Today:
      0.000p
  • 52 Week High: 4.05
  • 52 Week Low: 0.75
  • Currency: UK Pounds
  • Shares Issued: 427.35m
  • Volume: 1,405,000
  • Market Cap: £3.42m
  • RiskGrade: 304

Evgen Pharma Overview

Evgen is a clinical stage drug development company focused on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation.

1 Day Chart (23-04-2024)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -1154.8% -950.0%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 7.7 8.3
Pr/Book 0.6  
Latest F'cast
Revenue n/a -9.5%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Evgen Pharma Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-19 n/a (3.12) (2.70)p n/a n/a n/a n/a 0.0%
31-Mar-20 n/a (3.17) (2.07)p n/a n/a n/a n/a 0.0%
31-Mar-21 0.19 (3.21) (1.82)p n/a n/a n/a n/a 0.0%
31-Mar-22 n/a (3.17) (0.99)p n/a n/a n/a n/a 0.0%
31-Mar-23 0.44 (5.01) (1.47)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Evgen Pharma Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-24 0.40 (3.80) (1.00)p n/a n/a n/a n/a 0.0%
31-Mar-25 n/a (1.40) (0.20)p n/a n/a n/a n/a 0.0%
31-Mar-26 n/a (2.20) (0.40)p n/a n/a n/a n/a 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

Evgen Pharma Company Announcements

Holding(s) in Company 22-Apr-2024 10:11 RNS
Holding(s) in Company 11-Apr-2024 15:04 RNS
Holding(s) in Company 09-Apr-2024 07:00 RNS

Evgen Pharma ShareCast News

Evgen upbeat on start of glioblastoma research p... 26-Oct-2023 ShareCast
Evgen Pharma doses first volunteers in SFX-01 tr... 16-Nov-2022 ShareCast
Evgen starts recruiting volunteers for trial of ... 12-Oct-2022 ShareCast

Latest Evgen Pharma Director Deals

Traded Action Notifier PriceAmountValue
05-Apr-24 Buy Susan (Sue) Foden 1.00p 600,000 £6,000.00
05-Apr-24 Buy Toni Hänninen 1.00p 1,000,000 £10,000.00
05-Apr-24 Placing Huw Jones 1.00p 3,000,000 £30,000.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Evgen Pharma Market Data

Currency UK Pounds
Share Price 0.80p
Change Today 0.000p
% Change 0.00 %
52 Week High 4.05
52 Week Low 0.75
Volume 1,405,000
Shares Issued 427.35m
Market Cap £3.42m
RiskGrade 304

Evgen Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
19.68% above the market average19.68% above the market average19.68% above the market average19.68% above the market average19.68% above the market average
84.91% above the sector average84.91% above the sector average84.91% above the sector average84.91% above the sector average84.91% above the sector average
Price Trend
92.89% below the market average92.89% below the market average92.89% below the market average92.89% below the market average92.89% below the market average
78.95% below the sector average78.95% below the sector average78.95% below the sector average78.95% below the sector average78.95% below the sector average
Income Not Available
Growth Not Available

Evgen Pharma Dividends

No dividends found

Trades for 23-Apr-2024

Time Volume / Share Price
15:26 1,200,000 @ 0.83p
11:20 10,000 @ 0.83p
08:01 195,000 @ 0.83p

Evgen Pharma Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page